Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEY...

por Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., Rey, Felipe, Chiu, Kun-Yuan, Roubaud, Guilhem, Kramer, Gero, Sumitomo, Makoto, Massari, Francesco, Suzuki, Hiroyoshi, Qiu, Ping, Zhang, Jinchun, Kim, Jeri, Poehlein, Christian H., Yu, Evan Y.
Publicado 2023

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

por Stockler, Martin R., Martin, Andrew J., Davis, Ian D., Dhillon, Haryana M., Begbie, Stephen D., Chi, Kim N., Chowdhury, Simon, Coskinas, Xanthi, Frydenberg, Mark, Hague, Wendy E., Horvath, Lisa G., Joshua, Anthony M., Lawrence, Nicola J., Marx, Gavin M., McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A., Parnis, Francis, Parulekar, Wendy R., Pook, David W., Reaume, M. Neil, Sandhu, Shahneen, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G., Winter, Diana G., Yip, Sonia, Zhang, Alison Y., Zielinski, Robert R., Sweeney, Christopher J.
Publicado 2022